Regeneron Pharmaceuticals expects to see downward pressure on the 2mg version of Eylea (aflibercept) continue after 2024, but demand for the VEGF inhibitor has remained high despite the introduction of the first aflibercept biosimilar.
Regeneron’s Eylea Faces Pressure, But Pipeline Shows Strength
The drug maker’s top-selling Eylea franchise faces market challenges as biosimilars roll out, but Regeneron is confident about a pipeline that includes multiple significant catalysts in 2025.
